Harnessing $^{64}$Cu/$^{67}$Cu for a theranostic approach to pretargeted radioimmunotherapy

Outi Keinänen,a,b Kimberly Fung,a, James M. Brennan,c Nicholas Zia,a Matt Harris,a Ellen van Dam,a,b Colin Biggin,a Amos Hett,a Jon Stoner,a Paul S. Donnelly,a,b Jason S. Lewis,a,b,c,d Brian M. Zeglis,a,b,c,d

aDepartment of Chemistry, Hunter College, The City University of New York, New York, NY 10021; bDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065; cPhD Program in Chemistry, Graduate Center of the City University of New York, New York, NY 10016; dSchool of Chemistry and Bio21 Molecular Science Institute, University of Melbourne, Melbourne, VIC 3010, Australia; eClarity Pharmaceuticals, Sydney, NSW 2042, Australia; fIdaho Accelerator Center, Idaho State University, Pocatello, ID 83201; gDepartment of Radiology, Weill Cornell Medical College, New York, NY 10021; and hProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065

Edited by Jacqueline K. Barton, California Institute of Technology, Pasadena, CA, and approved September 24, 2020 (received for review May 18, 2020)

Over the past decade, theranostic imaging has emerged as a powerful clinical tool in oncology for identifying patients likely to respond to targeted therapies and for monitoring the response of patients to treatment. Herein, we report a theranostic approach to pretargeted radioimmunotherapy (PRIT) based on a pair of radioisotopes of copper: positron-emitting copper-64 ($^{64}$Cu, $t_{1/2} = 12.7$ h) and beta particle-emitting copper-67 ($^{67}$Cu, $t_{1/2} = 61.8$ h). This strategy is predicated on the in vivo ligation between a trans-cyclooctene (TCO)-bearing antibody and a tetrzine (Tz)-based radioligand via the rapid and bioorthogonal inverse electron-demand Diels–Alder reaction. Longitudinal therapy studies were conducted in a murine model of human colorectal carcinoma using an immun conjugate of the huA33 antibody modified with TCO (huA33-TCO) and a $^{67}$Cu-labeled Tz radioligand ($^{67}$Cu-Cu-MeCOSar-Tz). The injection of huA33-TCO followed 72 h later by the administration of 18.5, 37.0, or 55.5 MBq of $^{64}$Cu-Cu-MeCOSar-Tz produced a dose-dependent therapeutic response, with the median survival time increasing from 68 d for the lowest dose to >200 d for the highest. Furthermore, we observed that mice that received the highest dose of $^{64}$Cu-Cu-MeCOSar-Tz in a fractionated manner exhibited improved hematological values without sacrificing therapeutic efficacy. Dual radionuclide experiments in which a single administration of huA33-TCO was followed by separate injections of $^{64}$Cu-Cu-MeCOSar-Tz and $^{67}$Cu-Cu-MeCOSar-Tz revealed that the positron emission tomography images produced by the former accurately predicted the efficacy of the latter. In these experiments, a correlation was observed between the tumor uptake of $^{64}$Cu-Cu-MeCOSar-Tz and the subsequent therapeutic response to $^{64}$Cu-Cu-MeCOSar-Tz.

Significance

Radioimmunotherapy is predicated on harnessing the exquisite specificity of antibodies to deliver cytotoxic radiation to tumors. Yet the long circulation time of radioimmunoconjugates leads to high radiation doses to healthy tissues. Pretargeted radioimmunotherapy (PRIT) circumvents this problem by decoupling the antibody and radionuclide, injecting the former prior to the latter, and empowering the two components to combine at the tumor. We have leveraged bioorthogonal click chemistry, a colorectal cancer-targeting antibody, and a pair radioisotopes of copper—positron-emitting copper-64 and beta particle-emitting copper-67—to create a pretargeting system that enables both theranostic positron emission tomography and PRIT. We believe that the incorporation of theranostic imaging into PRIT regimens could be instrumental in the clinical success of the modality.

Author contributions: O.K. and B.M.Z. designed research; O.K., K.F., and J.M.B. performed research; N.Z., M.H., E.v.D., A.H., and C.B. contributed new reagents/analytic tools; O.K. and B.M.Z. analyzed data; and O.K. and B.M.Z. wrote the paper.

Competing interest statement: E.v.D., M.H., A.H., and C.B. are/were employed by Clarity Pharmaceuticals. P.S.D. and J.S.L. serve on the Scientific Advisory Board of Clarity Pharmaceuticals. P.S.D. and N.Z. are inventors of intellectual property in this research; N.Z., M.H., E.v.D., C.B., A.H., J.S., P.S.D., and J.S.L. contributed new reagents/analytic tools.

This article is a PNAS Direct Submission.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

To whom correspondence may be addressed. Email: bz102@hunter.cuny.edu.

This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2009960117/-/DCSupplemental.
optimal biodistribution in the body. This means that antibodies must be labeled with radionuclides with long physical half-lives in order to ensure that sufficient radioactivity remains once the radioimmunoconjugate has reached the tumor. Several therapeutic radionuclides with multiday half-lives are readily available, including $^{177}$Lu ($t_{1/2} \sim 6.7$ d), $^{131}$I ($t_{1/2} \sim 8.0$ d), and $^{225}$Ac ($t_{1/2} \sim 9.9$ d). Yet this combination of sluggish pharmacokinetics and long radionuclidic half-lives can lead to high radiation doses to healthy tissues, a trait which has hampered the widespread clinical implementation of RIT.

One approach to circumventing this issue is in vivo pretargeting (28–30). In vivo pretargeting is predicated on decoupling the antibody and the radionuclide, injecting the two components separately, and empowering them to combine in vivo at the tumor. More specifically, a specialized antibody capable of binding both a cancer antigen and a radiolabeled small molecule is injected first. Then, after this antibody has been given time (often several days) to accumulate in the tumor and clear from the blood, the radiolabeled small molecule is administered. This second component travels through the bloodstream quickly, either ligating with the antibody at the tumor or rapidly clearing from the body. This approach shifts the radionuclide from the immunoglobulin—where it resides during traditional immunoPET and RIT—to a rapidly clearing small molecule. As a result, a radionuclide with a multiday physical half-life is no longer needed, a change which simultaneously facilitates the use of short-lived nuclides that are normally incompatible with antibodies and reduces radiation dose rates to healthy tissues.

Over the last several years, our laboratories and others have developed an approach to in vivo pretargeting based on the rapid and bioorthogonal inverse electron-demand Diels–Alder click reaction between trans-cyclooctene (TCO) and tetrazine (Tz) (Fig. 1A) (31–36). Broadly speaking, this methodology consists of four steps: 1) the administration of a monoclonal antibody (mAb)-TCO immunoconjugate; 2) an interval period during which the antibody accumulates at the tumor and clears from the blood; 3) the injection of a small molecule Tz-based radioligand; and 4) the in vivo click ligation between two components, followed by the rapid clearance of any excess radioligand. This strategy has proven highly effective for pretargeted PET imaging (36–49) as well as pretargeted radioimmunotherapy (PRIT) using beta-emitting ($^{177}$Lu) and alpha-emitting ($^{225}$Ac) radionuclides (50–55). Yet as the field stands poised to make the jump further purification. All experiments involving laboratory animals were performed in accordance with a protocol approved by Hunter College, Weill Cornell Medical College, and Memorial Sloan Kettering Cancer Center.

Fig. 1. (A) The inverse electron demand Diels–Alder (IEDDA) reaction between trans-cyclooctene and tetrazine. (B) The structure of Cu-MeCOSar-Tz.

is followed by the sequential injection of two Tz-bearing radioligands: one for theranostic PET and a second for endoradiotherapy (Fig. 2). The key to this investigation is a pair of radioisotopes of copper that allows us to create radioligands that are completely identical except for the number of neutrons within the copper atom: copper-64 ($^{64}$Cu, $t_{1/2} = 12.7$ h) and copper-67 ($^{67}$Cu, $t_{1/2} = 61.8$ h) (Fig. 1B). While $^{64}$Cu is a relatively well-known positron-emitting nuclide, $^{67}$Cu produces beta particles ($E_{\beta} = 141$ keV) that are suitable for endoradiotherapy as well as gamma rays (185 keV, 49%; 93 keV, 16%) that can be imaged via SPECT. For years, challenges in the large-scale production of $^{67}$Cu have impeded its use in nuclear medicine, although recent advances are expected to dramatically increase its availability (56, 57). Furthermore, the advent of highly stable copper chelators based on bicyclo[6.6.6]icosane—termed “sarcophagines”—has also reinvigorated interest in $^{68}$Cu as a therapeutic radionuclide, as illustrated by the recent development of $^{64/67}$CuCu-SarTATE for the PET imaging and peptide receptor radiotherapy of patients with neuroendocrine tumors (58–61).

To provide a bird’s-eye view of the investigation, we first synthesized and characterized the two radioligands—$^{64}$CuCu-MeCOSar-Tz and $^{64}$CuCu-MeCOSar-Tz—as well as a TCO-bearing immunoconjugate of the huA33 antibody, a noninternalizing humanized mAb that targets a transmembrane glycoprotein (i.e., the A33 antigen) expressed by the vast majority of colorectal cancers (62–65). HuA33-TCO and $^{64}$CuCu-MeCOSar-Tz were then employed to perform biodistribution and longitudinal tumor penetration studies in a murine model of colorectal cancer in order to determine the dosimetry and validate the efficacy of $^{64}$Cu-based PRIT. Finally, in vivo pretargeting experiments were performed using $^{64}$CuCu-33-TCO in conjunction with both radioligands to interrogate the therapeutic efficacy of the dual isotope strategy as well as the predictive value of theranostic PET in this schema.

We have demonstrated that this innovative approach to PRIT is highly effective in vivo and may thus furnish a roadmap for how theranostic imaging may be used to supplement this methodology in the clinic. Our approach to in vivo pretargeting employs an isotopologous pair of radioligands for theranostic PET imaging and endoradiotherapy. This is absolutely critical in the context of clinical translation, as the use of a single, structurally unique radioligand—rather than two chemically distinct constructs labeled with different radioelements—will simplify the collection of pharmacology and toxicology data and streamline the regulatory review process.

Materials and Methods

All reagents were purchased from commercial suppliers and used without further purification. All experiments involving laboratory animals were performed in accordance with a protocol approved by Hunter College, Weill Cornell Medical College, and Memorial Sloan Kettering Cancer Center.
Institutional Animal Care and Use Committees. A detailed description of experimental procedures—including synthetic protocols, bioconjugation techniques, radiolabeling methodologies, and the design and execution of in vivo experiments—can be found in the SI Appendix.

**Synthesis of MeCOSar-Tz.** MeCOSar-NHS was prepared as previously described (66, 67). Briefly, to a solution of MeCOSar-NHS (0.053 mmol) in dimethylformamide (DMF; 530 μL) was added benzylaminotetrazine hydrochloride (11.8 mg, 0.053 mmol) and diisopropylethylamine (18.4 μL, 0.11 mmol). The reaction volume of the reaction mixture was increased to 1 mL with DMF, and the reaction was stirred for 1 h at 60 °C in the absence of light. The product—MeCOSar-Tz—was purified by reversed-phase high performance liquid chromatography (HPLC). Analysis of the fractions by HPLC-electrospray ionization mass spectrometry (ESI-MS) identified those containing the product, and these fractions were lyophilized to afford MeCOSar-Tz·CF3CO2 as a fluffy pink powder (12 mg, ∼38%), ESI-MS [C29H49N12O22]+ = 597.410; [C29H50N12O22]2+ = 299.208; HPLC RT = 13.8 min, 0 to 25% solvent B [solvent A: H2O, 0.1% trifluoroacetic acid (TFA); solvent B: CH3CN, 0.1% TFA] over 25 min.

The reaction volume of the reaction mixture was increased to 1 mL with DMF, and the reaction was stirred for 1 h at 60 °C in the absence of light. The product—MeCOSar-Tz—was purified by reversed-phase high performance liquid chromatography (HPLC). Analysis of the fractions by HPLC-electrospray ionization mass spectrometry (ESI-MS) identified those containing the product, and these fractions were lyophilized to afford MeCOSar-Tz·CF3CO2 as a fluffy pink powder (12 mg, ∼38%), ESI-MS [C29H49N12O22]+ = 597.410; [C29H50N12O22]2+ = 299.208; HPLC RT = 13.8 min, 0 to 25% solvent B [solvent A: H2O, 0.1% trifluoroacetic acid (TFA); solvent B: CH3CN, 0.1% TFA] over 25 min.

**Fig. 2.** PRIT. Illustration of the theranostic approach to PRIT. The immunoconjugate (huA33-TCO) is injected first and given time to slowly accumulate at the tumor and clear from the blood. After this interval, the 64Cu-labeled radioligand is injected. It then clicks with the huA33-TCO at the tumor and clears rapidly from the blood, enabling theranostic PET imaging. Next, the 67Cu-labeled radioligand is administered, and it likewise is given time to react with the tumor-bound immunoconjugate and clear from the system, thus beginning the therapeutic irradiation of the tumor tissue. PRIT can be performed without theranostic imaging by omitting the administration of the diagnostic radioligand.
Radiolabeling of MeCoSar-Tz. MeCoSar-Tz was radiolabeled with $[{^{64}}\text{Cu}]$Cu$^{2+}$ or $[{^{67}}\text{Cu}]$Cu$^{2+}$ by diluting the stock solution (0.36 mg/ml in dimethylsulphoxide) into ammonium acetate buffer (200 mM, pH 5.5, 200 to 300 μl) prior to the addition of $[{^{64}}\text{Cu}]$CuCl$_2$ in 0.05 M HCl or $[{^{67}}\text{Cu}]$CuCl$_2$ in 0.01 M HCl. The labeling solution was incubated on an agitating thermomixer at 500 x g for 20 min at 37 °C. The progress of the radiolabeling reaction was assessed via instant thin layer chromatography (ITLC), which revealed quantitative labeling with >99% radiochemical purity. Thus, no further purification was necessary.

Tumor Model. All in vivo studies were carried out in female, athymic nude mice (5 to 7 wk old, The Jackson Laboratory). Mice were xenografted subcutaneously (s.c.) on the right flank with 5 to 10.0 MBq, 0.7 nmol). At 4, 24, 48, and 72 h after the injection of $[{^{67}}\text{Cu}]$Cu-MeCOSar-Tz, the mice were weighed, and assayed for radioactivity with a gamma counter calibrated for $^{67}$Cu using known standards.

In biodistribution experiments with directly radiolabeled huA33, $[{^{60}}\text{Cu}]$Cu-MeCOSar-Tz-TCO-huA33 (1.9 MBq, 100 μg, 0.7 nmol) was administered via i.v. tail-vein injection. At 4, 24, 72, and 120 h post injection, the mice were killed, and their organs were collected, weighed, and assayed for radioactivity with a gamma counter calibrated for $^{60}$Cu using known standards.

Dosimetry Calculations. The average activity concentration from five tissue samples from each time point was fitted to a biexponential function to create time-activity curves (TAC). For most tissues, the best TAC fit utilized a one- or two-phase exponential decay model. One tissue—the tumor—exhibited marked uptake over the time course of the experiment, and, therefore, a trapezoidal model was used up to the last time point, after which it was assumed (due to the residualizing nature of $[{^{64}}\text{Cu}]$Cu$^{2+}$) that clearance was determined entirely by radioactive decay. The cumulative uptake in each tissue was calculated from the areas under the time-activity curves. Absorbed doses to the tumor and all healthy organs were estimated assuming absorbed fractions of 1 for the $\beta$-emissions of $^{60}$Cu and of 0 for the penetrating photon emissions and using an equilibrium absorbed dose constant of 0.33 g x Rad/g x h.

Longitudinal Radiotherapy Studies. In the longitudinal radiotherapy studies, three control cohorts, four PRIT cohorts, one therapeutic PRIT cohort, and one traditional RIT cohort were employed ($n = 10$). The first control cohort received only saline, the second received only huA33-TCO (100 μg, 0.7 nmol, 5 TCO/mAb), and the third received only $[{^{64}}\text{Cu}]$Cu-MeCOSar-Tz (55.5 MBq, 0.7 nmol). The injection day was designated day 0 of the experiment. A 72-h injection interval was chosen for the longitudinal therapy study because it produced lower activity concentrations in the blood. All animals in the PRIT cohorts were administered huA33-TCO (100 μg, 0.7 nmol, 5 TCO/mAb) and the third received only $[{^{64}}\text{Cu}]$Cu-MeCOSar-Tz (55.5 MBq, 0.7 nmol). Each mouse was killed, and their organs were collected, weighed, and assayed for radioactivity with a gamma counter calibrated for $^{64}$Cu using known standards.

Ex Vivo Biodistribution Experiments. For pretargeting biodistribution experiments, the mice were injected via the lateral tail vein with huA33-TCO (100 μg, 0.7 nmol, 5 TCO/mAb) and $[{^{60}}\text{Cu}]$Cu-MeCOSar-Tz (9.3 to 10.0 MBq, 0.7 nmol). At 4, 24, 48, and 72 h after the injection of $[{^{60}}\text{Cu}]$Cu-MeCOSar-Tz, the mice were weighed, and assayed for radioactivity with a gamma counter calibrated for $^{60}$Cu using known standards.

Ex Vivo Biodistribution. With the synthesis and characterization of the components complete, the next step was to evaluate the in vivo performance of the system. But before we could move on to the dual isotope theranostic strategy, it was critical to first establish the efficacy of PRIT with huA33-TCO and $[{^{64}}\text{Cu}]$Cu-MeCOSar-Tz alone. This process began with pretargeted biodistribution experiments designed to probe the pharmacokinetic profile of $[{^{64}}\text{Cu}]$Cu-MeCOSar-Tz, determine the optimal interval time between the injections of immunonjugate and radioligand, and facilitate the calculation of the radiation dose rates to body weight. Five possible end points of the study were defined: 1) if the longest dimension of the tumor reached 1 cm; 2) if the tumor started to hamper the movement of the mouse; respectively. A tumor volume of ≤40 mm$^3$ was considered as a successful treatment outcome. The radioligand was injected on day 0 of the experiment. The mice were then injected with a solution containing a 1:1 mixture of Matrigel (Corning Life Sciences) and cell culture medium. The tumor reached the ideal size for experiments (∼100 mm$^3$) after ∼14 d.

Results

Bionjugation, Synthesis, and Radiochemistry. The first step of the investigation was the assembly of the molecular components of our in vivo system. To this end, huA33-TCO was synthesized according to published procedures via the reaction of an N-hydroxysuccinimide–bearing variant of TCO with the parent antibody, ultimately producing the immunonjugate with a degree of labeling of 5.2 ± 0.1 TCO/mAb and an immunoreactivity of 88.9 ± 1.8% ($n = 5$) as determined via matrix-assisted laser desorption ionization time-of-flight mass spectrometry and in vitro autoradiographic analysis. The immunonjugate activity of $^{64}$Cu-TCO was measured using RadioPalm (HPLC) and confirmed that no significant aggregation had occurred during the biodistribution process (SI Appendix, Fig. S1). For the radioligand, we paired Tz with MeCoSar, a member of the sarcophagine family that exhibits exceptional in vitro and in vivo stability as a chelator for the radioisotopes of copper (58-61, 67-69). MeCoSar-Tz was synthesized and purified according to published procedures and isolated with a yield of ∼38%. The radiolabeling of MeCoSar-Tz was performed identically with both radioisotopes via the incubation of the precursor with $[{^{64}}\text{Cu}]$CuCl$_2$ or $[{^{67}}\text{Cu}]$CuCl$_2$ in ammonium acetate buffer (200 mM, pH 5.5) for 20 min at 37 °C. $[{^{64}}\text{Cu}]$Cu-MeCOSar-Tz was ultimately isolated in quantitative radiochemical yield, a radiochemical purity of >99%, and a molar activity of 15.3 to 16.5 GBq/μmol, while $[{^{67}}\text{Cu}]$Cu-MeCOSar-Tz was produced in quantitative radiochemical yield, a radiochemical purity of >99%, and a molar activity of 74.1 to 82.3 GBq/μmol. It is important to note that in all of the in vivo pretargeting experiments performed for this investigation, the molar activity of the radioligand was adjusted to ensure that each injection contained 0.7 nmol of Tz, as a 1:1 ratio of immunoconjugate:radio ligand has been shown to provide superior in vivo results compared to approaches that use a vast excess of either component (70). Finally, $[{^{60}}\text{Cu}]$Cu-MeCOSar-huA33 was synthesized in order to provide a directly radiolabeled antibody control for the biodistribution and longitudinal therapy experiments. $[{^{60}}\text{Cu}]$Cu-MeCOSar-Tz was reacted with huA33-TCO for 0.5 h at 37 °C, and the reaction solution was purified via size exclusion chromatography (Sephadex G-25M, PD-10 column, GE Healthcare; dead volume: 2.5 mL, eluted with 2 mL of phosphate-buffered saline, pH 7.4) to provide the final radioimmunoconjugate in an isolated radiochemical yield of 49%, a radiochemical purity of >99%, and a specific activity of 32.1 GBq/μmol.

Ex Vivo Biodistribution. As a result of the successful synthesis and characterization of the components complete, the next step was to evaluate the in vivo performance of the system. But before we could move on to the dual isotope theranostic strategy, it was critical to first establish the efficacy of PRIT with huA33-TCO and $[{^{64}}\text{Cu}]$Cu-MeCOSar-Tz alone. This process began with pretargeted biodistribution experiments designed to probe the pharmacokinetic profile of $[{^{64}}\text{Cu}]$Cu-MeCOSar-Tz, determine the optimal interval time between the injections of immunonjugate and radioligand, and facilitate the calculation of the radiation dose rates to...
the tumor and healthy organs. To this end, athymic nude mice bearing s.c. A33 antigen-expressing SW1222 human colorectal carcinoma xenografts were administered huA33-TCO (100 μg, 0.7 nmol) and then—following an interval of either 24 or 72 h—[67Cu]Cu-MeCOSar-Tz (9.3 to 10.0 MBq, 0.7 nmol). In addition, a control arm of the experiment was performed in which tumor-bearing mice were administered the same dose of [67Cu]Cu-MeCOSar-Tz alone. After 4, 24, 48, and 72 h, the cohorts (n = 5 per time point) were killed, and the tumor as well as selected organs were harvested, washed, dried, and assayed for 67Cu on a gamma counter (Fig. 3A and SI Appendix, Tables S1–S3).

In the absence of huA33-TCO, [67Cu]Cu-MeCOSar-Tz cleared quickly from the blood and healthy organs, was eliminated via the urine, and produced negligible tumoral uptake (i.e., 0.2 ± 0.1%ID/g at 72 hours post injection [h.p.i.]). In contrast, high-activity concentrations in the tumor were observed in the mice treated with both huA33-TCO and [67Cu]Cu-MeCOSar-Tz, with values reaching 10.2 ± 2.1%ID/g (24-h interval) and 9.2 ± 1.3%ID/g (72-h interval) at 72 h.p.i. In these same mice, the residual activity concentration in the blood decreased over the course of the experiment, starting around 3 to 4%ID/g at 4 h.p.i. and reaching 0.5 to 1.0%ID/g at 120 h.p.i. The uptake in other tissues remained relatively low throughout the study, with the liver the healthy organ with the highest level of uptake (4.1 to 3%ID/g). Taken together, these data indicate that high tumor-to-healthy organ activity concentration ratios, e.g., tumor-to-blood, -muscle, -liver, and -large intestine ratios of 20.2 ± 7.7, 159.2 ± 35.6, 6.0 ± 1.6, and 66.8 ± 37.7 at 120 h.p.i. for the cohort with a 72-h injection interval.

Dosimetry. Radiation dose rates and therapeutic indices for both pretargeting intervals were calculated from the biodistribution data (Fig. 3B). In addition, a biodistribution experiment was performed with directly labeled [67Cu]Cu-huA33 and employed for dosimetry calculations (SI Appendix, Figs. S2 and Table S4). As expected, both pretargeting approaches yielded reductions in radiation dose rates compared to the directly radiolabeled antibody. For example, the pretargeting strategy with a 72-h interval produces dose rates of 5.9 and 14.2 cGy/MBq to the blood and liver, respectively, while [67Cu]Cu-huA33 creates dose rates of 77.7 and 16.1 cGy/MBq to the same organs. However, significant decreases in the radiation dose rates to the tumor in the pretargeting cohorts (63.0 and 57.2 cGy/MBq for 24-h and 72-h intervals, respectively) compared to the cohort that received the directly labeled antibody (574.5 cGy/MBq) mean that the therapeutic indices—i.e., the ratios of the radiation dose rates to the tumor to the radiation dose rates to specific healthy tissues—for all three methodologies lie in similar ranges. To wit, while pretargeting with a 24-h interval produces a tumor-to-blood therapeutic index (6.5) below that of the directly labeled antibody (8.1), the pretargeting strategy with a 72-h interval yields the highest therapeutic index (9.7) of all three. In the end, given its highest tumor-to-blood therapeutic index, the 72-h PRIT strategy was selected for longitudinal therapy studies.

Longitudinal Radiotherapy. Longitudinal radiotherapy studies were performed to interrogate the efficacy and safety of this approach (<PRIT>). These experiments initially employed eight different cohorts (n = 10) of mice bearing s.c. SW1222 human colorectal cancer xenografts (Fig. 4A). The three PRIT cohorts received huA33-TCO (100 μg, 0.7 nmol) followed 72 h later by three different doses of [67Cu]Cu-MeCOSar-Tz: 18.5, 37.0, or 55.5 MBq (in each case, 0.7 nmol). In contrast, the three control cohorts received the vehicle (0.9% sterile saline) alone, huA33-TCO alone, or [67Cu]Cu-MeCOSar-Tz alone (55.5 MBq). In order to probe the value of fractionated dosing, a seventh cohort received huA33-TCO (100 μg, 0.7 nmol) followed 72 h later by two 27.8-MBq doses of [67Cu]Cu-MeCOSar-Tz separated by 48 h. Finally, an eighth, “traditional PRIT” cohort received a single dose of [67Cu]Cu-MeCOSar-Tz-TCO-huA33 (18.5 MBq).

While the growth of the tumors in the control cohorts continued unabated throughout the study, the tumors within the mice of the PRIT and RIT cohorts exhibited a short initial period of growth followed by a dramatic reduction in volume (Fig. 4B). Indeed, all of the mice in the radiotherapy cohorts ultimately reached a point at which their xenografts were smaller than they had been on day 0. A dose-dependent therapeutic response was observed among the three single-dose PRIT cohorts, with the group receiving 55.5 MBq of [67Cu]Cu-MeCOSar-Tz exhibiting the most significant regrowth delay. Similar regrowth delay was found in the mice that received 18.5 MBq of the conventional radioimmunoconjugate, [67Cu]Cu-huA33. Finally, the response of the mice receiving fractionated PRIT largely mirrored that of the 55.5-MBq PRIT cohort.

The efficacy of each treatment regimen is most clearly visualized using a Kaplan–Meier plot (Fig. 4C). The median survival times of the control cohorts are 21 d (vehicle only), 21 d (huA33-TCO only), and 31.5 d ([67Cu]Cu-MeCOSar-Tz only). These values stand in stark contrast to the median survival times of the cohorts that received treatment: 68.5 d (single-dose PRIT, 18.5 MBq), 98.5 d (single-dose PRIT, 37.0 MBq), 200 d (single-dose PRIT, 55.5 MBq), 189 d (fractionated-dose PRIT), and 290 d (RIT). Statistical analysis of the data confirms significant differences (P values < 0.01) between the control groups and all of the radiotherapy cohorts as well as between the 18.5 and 37.0 MBq PRIT cohorts and the remaining three experimental groups. No statistically significant differences exist, however, between the survival of the 55.5-MBq PRIT, fractionated PRIT, and traditional RIT cohorts. While the vast majority of the mice killed during the study had tumors that exceeded the maximum permissible size, a handful of animals had to be killed—or were found dead—due to other pathologies (SI Appendix, Table S5). In light of the dosimetry data, body-weight measurements, and blood analysis (see Body Weight and Blood Analyses below), it is unlikely that these events stemmed from the endoradiotherapy itself but rather were related to the aging of the immunocompromised mice.

SPECT Imaging. In addition to its therapeutic 141-keV β-particle, 67Cu also emits 185 keV (49%) and 93 keV (16%) gamma rays that are suitable—although admittedly suboptimal—for SPECT imaging. In order to probe the potential of exploiting these emissions to visualize the 67Cu-based therapies, SPECT imaging was carried out for each cohort at 4, 24, 48, and 96 h after the administration of radioactivity (Fig. 5 and SI Appendix, Fig. S3). Fig. 5 contains representative SPECT maximum intensity projections (MIPs) from three cohorts: 55.5-MBq single-dose PRIT, fractionated-dose PRIT (27.8 + 27.8 MBq), and RIT (18.5 MBq). In the mice receiving fractionated doses of PRIT, the second dose of [67Cu]Cu-MeCOSar-Tz was administered after the 48-h SPECT scan, and the mice were imaged again 4 h (52 h after the first dose) and 48 h (96 h after the first dose) later. Taken together, these images illustrate several trends. First, the excretion of free [67Cu]Cu-MeCOSar-Tz through the urinary tract can be clearly visualized in the images collected at 4 h.p.i. Second, in all of the cohorts, the tumor is the tissue with the highest activity concentration after 24 h. Third, the tumoral activity concentration in the cohort receiving fractionated PRIT increases following the administration of the second dose, underscoring the viability of this approach. Finally, as expected, the cohort that was administered directly labeled [67Cu]Cu-huA33 exhibited elevated activity concentrations in the liver compared to the PRIT groups.

Body Weight and Blood Analyses. In order to assess the potential toxicity of this methodology, the body weight of each animal was measured twice per week. All of the mice—except for one in the
control cohort that received huA33-TCO only—maintained an acceptable body weight (>90% of original weight) throughout the course of the study (Fig. 6A). During the first 2 wk, slight decreases were observed in the body weight of the mice in the [67Cu]Cu-MeCOSar-Tz only, 55.5-MBq PRIT, fractioned-dose PRIT, and RIT cohorts, but this trend self-corrected soon thereafter. Generally speaking, however, the average weight loss did not exceed 5% for any of the radiotherapy cohorts, suggesting that this approach was well tolerated up to the highest doses tested.

In addition to monitoring the weight of the animals, an analysis of the blood of representative mice from each cohort was performed weekly (Fig. 6B and SI Appendix, Fig. S4). White blood cell (WBC) counts decreased initially in all of the cohorts that received doses of [67Cu], although these values recovered over the course of the experiment (Fig. 6B). The largest drop was observed in the 55.5-MBq single-dose PRIT cohort. Interestingly, when 55.5 MBq of [67Cu]Cu-MeCOSar-Tz was delivered as a fractioned dose—i.e., two doses of 27.8 MBq separated by 2 d—a smaller decrease in the WBC count occurred (P = 0.01.
at day 7). The RIT cohort, not surprisingly, exhibited a more substantial drop—and a more sluggish recovery—in WBC count than the PRIT cohort that received the same dose of radioactivity (18.5 MBq). Platelet counts likewise dropped for all of the cohorts that received \( ^{67}\text{Cu} \), but the most significant decrease occurred in the 55.5-MBq PRIT cohort (Fig. 6B). Furthermore, a more substantial decrease in platelet count was again observed in the cohort receiving RIT compared to the group receiving an equal dose of PRIT (\( P = 0.001 \) at day 14). Like the WBC counts, however, the decreased platelet count values recovered in all of the cohorts after the first 3 wk of the study.

**Incorporating Theranostic PET Imaging into \( ^{67}\text{Cu}-\text{PRIT} \).** The final step in the investigation was the in vivo evaluation of a dual isotope approach to PRIT that incorporates \( ^{64}\text{Cu} \)-based PET imaging as well as \( ^{67}\text{Cu} \)-based endoradiotherapy. To this end, a longitudinal therapy experiment was performed in which athymic nude mice bearing s.c. A33 antigen-expressing SW1222 were given three injections: huA33-TCO (100 \( \mu \)g, 0.7 nmol), followed 72 h later by...
The responses of individual mice seem to correlate with the level of MeCOSar-Tz, with radioactivity levels in the center of xenografted tumors exhibiting complete tumor remission. Finally, the SPECT images obtained from Cu-MeCOSar-Tz closely mirror the PET images, reinforcing the theranostic value of the latter.

**Discussion**

Radioimmunoconjugates have long held promise for targeted endoradiotherapy, yet their widespread clinical implementation has been hindered due to concerns over their high radiation dose rates to healthy tissues. In recent years, theranostic imaging has helped clinicians select patients for RIT and optimize the dose of radioimmunoconjugates to maximize their safety and efficacy. And, while the advent of companion imaging agents has undoubtedly moved the field forward, it has not eliminated the intrinsic problems of radiolabeled antibodies.

The overarching goal of this investigation was to create a pretargeted approach to endoradiotherapy capable of leveraging the advantages of antibodies and theranostic imaging while simultaneously skirting the pharmacokinetic—and, consequently, dosimetric—limitations of full-length immunoglobulins. Over the past 5 years, our laboratories have developed a strategy for in vivo pretargeting based on the rapid and bioorthogonal inverse electron-demand Diels–Alder ligation between a TCO-bearing immunoconjugate and a Tz-containing radioligand. We have confirmed the efficacy of this approach in several murine models of cancer using a variety of different antibodies and positron-, β-, and α-emitting radionuclides, including 68Ga, 177Lu, and 212Bi. Yet until recently, each of these demonstrations focused on only a single modality: PET or RIT.

As we shifted our attention to a theranostic approach to pretargeting, it became apparent that we would need to employ either a single radionuclide with emissions suitable for both imaging and therapy or a pair of radionuclides, each with emissions suitable to one of the two tasks. Given that the former are few and far between, we turned to the use of a radionuclide pair. Along these lines, we demonstrated the feasibility of dual-isotope pretargeting using 64Cu- and 177Lu-labeled tetrazines: [64Cu]Cu-SarAr-Tz and [177Lu]Lu-DOTA-PEG7-Tz (48). Without question, the single most important finding of this work is that the injection of a first radioligand does not adversely affect the tumoral uptake or overall biodistribution of a second radionuclide. To wit, in pretargeting experiments using a 48-h interval between the administration of huA33-TCO and [177Lu]Lu-DOTA-PEG7-Tz, activity concentrations of 5.2 ± 1.2, 9.0 ± 2.6, and 13.0 ± 2.8%ID/g were observed in the tumor at 4, 24, and 48 h.p.i. Under identical conditions—but with the injection of [64Cu]Cu-SarAr-Tz a day after the immunoconjugate and a day before the [177Lu]Lu-labeled radioligand—the tumoral activity concentrations of [177Lu]Lu-DOTA-PEG7-Tz were found to be all but identical: 4.9 ± 0.4, 11.3 ± 1.6, and 13.1 ± 2.7%ID/g at the same time points. This phenomenon is of paramount importance in the context of theranostics, as it ensures that a radioligand administered for imaging does not attenuate the uptake or efficacy of a radioligand administered for therapy (48, 52). Yet this 64Cu/177Lu-based strategy is ultimately suboptimal from a theranostic standpoint because the two radioligands are different and thus will exhibit different pharmacokinetic profiles and in vivo behavior. Furthermore, the use of 177Lu (t1/2 ~ 6.7 d) fails to take advantage of an important facet of in vivo pretargeting: the ability to use radionuclides with half-lives that are normally incompatible with antibodies.

In this work, in response to these issues, we employed two radioisotopes of copper—positron-emitting 64Cu and...
β-particle-emitting 67Cu—to create a pair of chemically identical radioligands: [64Cu]Cu-MeCOSar-Tz and [67Cu]Cu-MeCOSar-Tz. The use of radioligands that are isotopologues has two principal advantages. First, the in vivo behavior of the two radioligands will be identical, facilitating the use of the former as a predictor of the biodistribution of the latter. Second, the use of only a single chemical species as a radioligand (Cu-MeCOSar-Tz) will simplify toxicological testing and streamline the regulatory review process as a whole.

In light of our previous work, the biodistribution data for pretargeting with huA33-TCO and [67Cu]Cu-MeCOSar-Tz present relatively few surprises. Tumoral uptake of the radioligand is apparent at even the earliest time point and grows throughout the course of the experiment, suggesting that the 67Cu-labeled tetrasite is clicking with both tumor-bound huA33-TCO and circulating immunoconjugate that subsequently accumulates in the xenograft. The [67Cu]Cu-MeCOSar-Tz clears from the blood and healthy organs relatively quickly, ultimately yielding promising tumor-to-healthy organ activity concentration ratios across the board. From a dosimetry perspective, the 67Cu-PRIT strategy produces significantly reduced individual organ dose rates compared to the directly radiolabeled 67Cu-huA33. Decreases in radiation doses can also be seen when 67Cu-PRIT is compared to 177Lu-labeled huA33, arguably a more realistic comparison since 67Cu is seldom used to label full-length IgG for the clinic. To wit, the radiation dose rate to the blood for 67Cu-PRIT is estimated to be 5.9 cGy/MBq, compared to 71.3 cGy/MBq for 67Cu-huA33 and 67.7 cGy/MBq for 177Lu-huA33 (Fig. 3B and SI Appendix, Table S6). Unfortunately, however, 67Cu-PRIT also produces lower radiation doses to the tumor compared to directly labeled 67Cu-huA33 and 177Lu-huA33. As a result, the therapeutic indices for pretargeting are generally comparable to those of the traditional radioimmunoconjugates for most organs, and the critical tumor-to-blood therapeutic index for 67Cu-PRIT (9.7 with a 72-h interval) is only marginally higher than that of 67Cu-huA33 (8.1) and lies below that of 177Lu-huA33 (18.6). This is an area that can be improved upon in the future. Optimizing the timing of the methodology and the doses of each of the components, for example, could improve therapeutic indices by increasing dose rates to the tumor and/or decreasing dose rates to healthy organs. Furthermore, our laboratory and others have also explored the use clearing agents as a means of reducing activity concentrations in the blood and healthy organs; however, clearing agents, while effective, would inevitably add yet another element of complexity to an already complex system.

The longitudinal therapy studies provide a platform to compare the efficacy of the various treatment strategies. Most importantly, all of the radiotherapy cohorts exhibit statistically significant differences in mean survival time compared to all of the control cohorts. In addition, a statistically significant dose-dependent response was observed for the low-, medium-, and high-dose PRIT cohorts. Intriguingly, while a statistically significant difference was not observed between the median survival times of the 55.5-MBq PRIT (200 d) and fractionated PRIT (189 d) cohorts, four mice in the latter regrew tumors over the course of the experiment compared to only one in the former. This phenomenon likely stems from the fact that the fractionated dose cohort did not receive its second 27.8-MBq dose (bringing the total up to 55.5 MBq) until 120 h after the administration of huA33-TCO, potentially lowering the overall radiation dose to the tumor. Nonetheless, the SPECT imaging results for the fractionated PRIT cohort clearly illustrate that the second administration of the radioligand increases the activity concentration in the tumor, suggesting that fractionated dosing could be a viable approach if optimized further. The mean survival time of the 55.5-MBq PRIT cohort is also matched by the cohort receiving 18.5 MBq of [67Cu]Cu-huA33. The RIT cohort, however, does outperform the PRIT cohort receiving an identical 18.5-MBq dose, a result that is not surprising given the higher dose rate of RIT to tumor tissue. It is worth noting that equal dose comparisons were not performed between RIT and PRIT at the 37.0- and 55.5-MBq levels because the literature suggests that these doses of a 67Cu-labeled antibody would cause acute radiation toxicity in mice (71). Finally, the body-weight monitoring and blood analysis generally suggest that all of the radiotherapeutic strategies are well tolerated, although slight yet temporary dips in the body weight, WBC count, and platelet count were observed in the cohorts of mice receiving higher radiation doses.

Despite the promise of 67Cu-PRIT alone, the most exciting results from this study arguably arise from the experiments featuring our theranostic approach to PRIT. In the longitudinal therapy study, the cohort receiving theranostic 64/67Cu-PRIT had a mean survival time of >200 d, equal to that of the groups treated with 55.5-MBq PRIT and 18.5-MBq RIT. That said, four mice in the theranostic PRIT cohort exhibited tumor regrowth—three to the point of being killed and one only slightly—compared to one in the single-dose PRIT group that received the same dose of [64Cu]Cu-MeCOSar-Tz. In light of our previous finding that the administration of one radioligand does not impede the uptake of a second (48), it is unlikely that this phenomenon is related to the use of two injections in the
theranostic cohort. A more probable explanation may lie in the heterogeneity of the tumors or, more likely still, that the mice in the single-dose PRIT cohort received $[^{67}\text{Cu}]\text{Cu-MeCOSar-Tz}$ 72 h after the injection of huA33-TCO while those in the theranostic group received the $[^{64}\text{Cu}]\text{Cu-MeCOSar-Tz}$ 96 h after the administration of the immunoconjugate. The most critical finding, however, is that the PET imaging results could have allowed us to predict which of the mice would experience tumor regrowth. The four mice with the lowest levels of radioactivity in the tumor in the 48-h PET scans (3.0, 4.1, 5.6, and 6.8 kBq) were those whose tumors regrew. In contrast, all of the other members of the cohort—whose xenografts contained $>9.0$ kBq of $[^{64}\text{Cu}]\text{Cu-MeCOSar-Tz}$—experienced complete and lasting shrinkage of their tumor tissue. In the end, while our previous work established the feasibility of dual radionuclide pretargeting, this investigation goes two critical steps further: demonstrating the therapeutic efficacy of $^{67}\text{Cu}$-PRIT and illustrating the usefulness of pretargeted $^{64}\text{Cu}$-PET as a predictive indicator of response to $^{67}\text{Cu}$-PRIT.

We believe that the data from this investigation lay out a clear road map for the incorporation of theranostic PET imaging into PRIT regimens. As pretargeted PET inches ever closer to the clinic—the first images from pancreatic cancer patients are expected in early 2021—one can easily envision how pretargeted imaging and therapy could be combined in the future: after the collection of initial PET scans, physicians could decide whether a patient is a suitable candidate for PRIT. If the tumoral standard uptake value (SUV) is above a predetermined threshold, the patient would then receive a dose of a therapeutic Tz radioligand. On the other hand, if the PET scan revealed insufficient uptake, the clinicians would pivot and pursue other therapeutic options.

Fig. 7. PRIT with theranostic PET. (A) Schematic of the theranostic PRIT experiment. (B) Coronal slice and MIP PET images of a representative mouse in the theranostic cohort at 4, 24, and 48 h post injection of $[^{64}\text{Cu}]\text{Cu-MeCOSar-Tz}$. The coronal slices intersect the center of the tumor. (C) SPECT-CT MIP images of the same representative mouse from the theranostic cohort collected at 4, 24, 48, and 96 h after the administration of $[^{64}\text{Cu}]\text{Cu-MeCOSar-Tz}$. (D) The tumor volume of each animal in the theranostic cohort as a function of time. The amount of radioactivity at the center of the tumor was determined via region of interest (ROI) analysis of PET image slices acquired at 48 h post injection.
Ultimately, we believe that this paradigm could be instrumental in the creation of safe and effective PET/CT strategies for colorectal cancer, pancreatic cancer, and beyond.

Data Availability. All study data are included in the article and SI Appendix.

1. U. Eberlein, M. Cremonesi, M. Lassmann, Individualized dosimetry for theranostics: Necessary, nice to have, or counterproductive? J. Nucl. Med. 58, 975–1035 (2017).
2. A. Yordanova et al., Theranostics in nuclear medicine practice. Oncotargets Ther. 10, 4821–4828 (2017).
3. H. Jadvar, X. Chen, W. Cai, U. Mahmood, Radiotheranostics in cancer diagnosis and management. Radiology 286, 388–400 (2018).
4. J. R. Ballinger, Theranostic radiopharmaceuticals: Established agents in current use. Br. J. Radiol. 91, 20170969 (2018).
5. A. G. Tervischa van Scheltinga et al., Preclinical efficacy of an antibody-drug conjugate targeting mesothelin correlates with quantitative 225Ac-ImmunopET. Mol. Cancer Ther. 16, 134–142 (2017).
6. H. Cho et al., A comparison of DFO and DFO* conjugated to trastuzumab-D51 for complexing 233U-235u for vitro stability and in vivo microPET/CT imaging studies in NOD/SCID mice with HER2-positive SK-OV-3 human ovarian cancer xenografts. Nucl. Med. Biol. 84-85, 1–9 (2018).
7. N. M. Di Bartolo, Z. Cai, M. Reilly, Tumor uptake and tumour blood ratios for 212Bi-DFO-trastuzumab-D51 on microPET/CT images in NOD/SCID mice with human breast cancer xenografts are directly correlated with HER2 expression and response to trastuzumab-D51. Nucl. Med. Biol. 67, 43–51 (2018).
8. C. Kratochwil, Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): The ZEPHIR trial. Ann. Oncol. 27, 619–624 (2016).
9. E. J. ter Weele et al., Imaging the distribution of an antibody-drug conjugate containing targeted mesothelin with 212Bi and IRDye 800CW in mice bearing human pancreatic cancer xenografts. Oncotarget 6, 42081–42090 (2015).
10. L. Lamberts et al., ImmunopET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody-drug conjugate treatment. Clin. Cancer Res. 22, 1642–1652 (2016).
11. P. Adumeau et al., Site-specifically labeled antibody-drug conjugate for simultaneous therapy and ImmunopET. Mol. Pharm. 15, 892–898 (2018).
12. B. M. Zeglis et al., Pretargeted radioimmunotherapy: A review. J. Mol. Sci. 5, 1388–1411 (2016).
13. E. J. ter Weele et al., Dual radionuclide therapy for colorectal cancer: Pathways to the clinic. J. Nucl. Med. 57, 1594–1602 (2016).
14. C. G. England et al., Preclinical pharmacokinetics and biodistribution studies of 212Bi-labeled pembrolizumab. J. Nucl. Med. 58, 162–168 (2017).
15. A. Kjaer, U. Krigne, Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. Scand. J. Gastroenterol. 50, 740–747 (2015).
16. M. Schottelius et al., Towards in-spiral cyclo-penta D. Comparative preclinical evaluation of [18F]GaDOTATATE and [18F]GaHA-DOTATE. EJNMMI Res. 5, 23 (2015).
17. A. Afshar-Oromieh et al., The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: Biodistribution in humans, radiodiagnosis, and first evaluation of tumor volumes. J. Nucl. Med. 56, 157–1705 (2015).
18. C. Kratochwil et al., 225Ac-PSMA-617 for PSMA-targeted α-therapy radiation of metastatic castration-resistant prostate cancer. J. Nucl. Med. 57, 1941–1944 (2016).
19. S. Lütje et al., PSMA ligands for radionuclide imaging and therapy of prostate cancer: Clinical status. Theranostics 5, 3388–1401 (2015).
20. K. Rahbar, A. Afshar-Oromieh, H. Jadvar, H. Ahmadzadehfar, PSMA theranostics: Current status and future directions. Mol. Imaging 17, 153601218776068 (2016).
21. J. Zang et al., First-in-human study of 117Lu-Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 46, 148–158 (2019).
22. S. M. Larson, J. A. Carraquillo, N. K. Cheung, O. W. Press, Radioimmunotherapy of human tumors. Nat. Rev. Cancer 15, 347–360 (2015).
23. W. K. Tsai, A. M. Wu, Aligning physics and physiology: Engineering antibodies for radionuclide delivery. J. Labelled Comp. Radiopharm. 61, 693–714 (2018).
24. C. Bailly et al., Immunop-ET for clinical theranostic approaches. Int. J. Mol. Sci. 18, 57 (2016).
25. K. L. Moek et al., Theranostics using antibodies and antibody-related therapeutics. J. Nucl. Med. 58, 835–905 (2017).
26. M. Al-tai, R. Membrino, B. Cook, V. Tolmachev, R. M. Zeglis, Pretargeted imaging and therapy. J. Nucl. Med. 58, 1553–1559 (2017).
27. A. Rondon, F. Degoul, Antibody pretargeting based on bioorthogonal click chemistry for cancer imaging and targeted radionuclide therapy. Bioconjug. Chem. 31, 159–173 (2020).
28. E. J. L. Steen et al., Pretargeting in nuclear imaging and radionuclide therapy: Improving imaging of theranostics and nanomedicines. Biomaterials 179, 209–245 (2018).

Acknowledgments. We thank the NIH for their generous support of Grant R01CA240963 (B.M.Z., J.S.L.), U01CA221046 (B.M.Z., J.S.L.), R01CA200167 (B.M.Z., J.S.L.), and R35 CA232130 (J.S.L.). The Thompson Family Foundation (JSL) as well as the Memorial Sloan Kettering Cancer Center Small Animal Imaging Core Facility and Radiochemistry and Molecular Imaging Probe Unit, which are supported by NIH Awards P03 CA08748 and 510 RRO20892-01, are also acknowledged.
61. C. Biggin, E. van Dam, M. Harris, M. Parker, G. Schembri, Estimating external exposure from patients after treatment with Cu-67 SARTATE. J. Nucl. Med. 60, 1624a (2019).
62. J. K. Heath et al., The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc. Natl. Acad. Sci. U.S.A. 94, 469-474 (1997).
63. S. Welt et al., Phase III study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. Clin. Oncol. 14, 1787-1797 (1996).
64. A. M. Scott et al., A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: Biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin. Cancer Res. 11, 4810-4817 (2005).
65. M. E. Ackerman et al., A33 antigen displays persistent surface expression. Cancer Immunol. Immunother. 57, 1017-1027 (2008).
66. K. Alt et al., Single-chain antibody conjugated to a cage amine chelator and labeled with positron-emitting copper-64 for diagnostic imaging of activated platelets. Mol. Pharm. 11, 2855-2863 (2014).
67. B. M. Paterson et al., PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate. Dalton Trans. 42, 1386-1396 (2014).
68. E. Gourni et al., Copper-64 labeled macrobicyclic sarcophagine coupled to a GRP receptor antagonist shows great promise for PET imaging of prostate cancer. Mol. Pharm. 12, 2781-2790 (2015).
69. R. J. Hicks et al., 64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. J. Nucl. Med. 60, 777-785 (2019).
70. S. M. van Duijnhoven et al., Diabody pretargeting with click chemistry in vivo. J. Nucl. Med. 56, 1422-1428 (2015).
71. G. L. DeKardt et al., Efficacy and toxicity of 62Cu-2IT-BAT-Lym-1 radio-immunoconjugate in mice implanted with human Burkitt’s lymphoma (Raji). Clin. Cancer Res. 3, 71-79 (1997).
Author/s:
Keinanen, O; Fung, K; Brennan, JM; Zia, N; Harris, M; van Dam, E; Biggin, C; Hedt, A;
Stoner, J; Donnelly, PS; Lewis, JS; Zeglis, BM

Title:
Harnessing Cu-64/Cu-67 for a theranostic approach to pretargeted radioimmunotherapy

Date:
2020-11-10

Citation:
Keinanen, O., Fung, K., Brennan, J. M., Zia, N., Harris, M., van Dam, E., Biggin, C., Hedt, A.,
Stoner, J., Donnelly, P. S., Lewis, J. S. & Zeglis, B. M. (2020). Harnessing Cu-64/Cu-67 for
a theranostic approach to pretargeted radioimmunotherapy. Proceedings of the National
Academy of Sciences of the United States of America, 117 (45), pp.28316-28327.
https://doi.org/10.1073/pnas.2009960117.

Persistent Link:
http://hdl.handle.net/11343/252244

File Description:
Published version

License:
CC BY-NC-ND